retatrutide clinical trials spain This weight-loss drug hasn't been approved by the FDA. Doctors are prescribing it anyway Is a new weight-loss drug
Description
Biosimilar semaglutide development programs have been announced by 14 manufacturers globally, including Samsung Bioepis , Biocon Biologics , Sandoz , Mylan and Viatris , Hikma , and multiple Chinese biotechnology companies
Nausea rates run higher than Retatrutide (44% vs 28%), and cardiovascular outcome data is more robust given longer market availability
Its not a discovery
In 2023, Pfizer provided medication and vaccine treatments to over 600 million patients worldwide
